• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.07% Nasdaq Up0.32%

    Portola Pharmaceuticals, Inc. (PTLA)

    48.19 Up 0.75(1.58%) Aug 28, 3:59PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Portola Pharmaceuticals, Inc.
    270 East Grand Avenue
    South San Francisco, CA 94080
    United States - Map
    Phone: 650-246-7000
    Fax: 650-246-7376
    Website: http://www.portola.com

    Index Membership:N/A
    Full Time Employees:99

    Business Summary 

    Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation. Its lead compound, Betrixaban, is an oral, once-daily Factor Xa inhibitor in Phase III clinical trial for venous thromboembolism prophylaxis in acute medically ill patients in-hospital and post discharge. The company’s other lead development candidate, Andexanet alfa, a recombinant protein that is in Phase III registration studies designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. It has collaboration agreements with Biogen Idec Inc.; Bristol-Myers Squibb Company; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; and Lee’s Pharmaceutical (HK) Ltd. The company is also developing Cerdulatinib, which is in Phase I/IIa proof-of-concept study, an orally available kinase inhibitor that inhibits spleen tyrosine kinase and janus kinases enzymes, which regulate signaling pathways, as well as for hematologic, or blood, cancers, and inflammatory disorders. In addition, it is involved in the development of PRT2607, a selective Syk inhibitor. The company was founded in 2003 and is headquartered in South San Francisco, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Portola Pharmaceuticals, Inc.

    Corporate Governance 
    Portola Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Aug 1, 2015 is 7. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 6; Compensation: 9.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. William Lis , 51
    Chief Exec. Officer, Pres and Director
    Ms. Mardi C. Dier , 51
    Chief Financial Officer and Exec. VP
    Dr. John T. Curnutte M.D., Ph.D., 63
    Exec. VP of R&D
    Mr. Jeet Mahal ,
    VP of Bus. Devel.
    Mr. Mark W. Gossett ,
    Sr. VP of Global Marketing
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders